Ustekinumab Maintained Clinically Meaningful Improvement in Health-Related Quality of Life in Patients with Moderate to Severe Crohn's Disease: Results from the IM-UNITI Long-Term Extension

(1) Icahn School of Medicine at Mount Sinai,New York,United States

(2) Janssen Global Services, LLC,Malvern,United States

(3) Janssen Scientific Affairs, LLC,Horsham,United States

(4) Janssen Research & Development, LLC,Spring House,United States

(5) Cedars-Sinai Med Ctr,Los Angeles,United States

(6) University of California,San Diego,United States

(7) Robarts Clinical Trials Inc.,London,Canada

This item was part of the IBD I (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019